Who are imidafenacin, KRP-197/ONO-8025's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tudorza Pressair, ACLIDINIUM, TIOTROPIUM, Budesonide/Glycopyrronium/Formoterol Fumarate, FF/UMEC/VI, umeclidinium 62.5 µg and vilanterol 25 µg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imidafenacin-krp-197-ono-8025.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

imidafenacin, KRP-197/ONO-8025 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

imidafenacin, KRP-197/ONO-8025 (imidafenacin, KRP-197/ONO-8025) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimuscarinic. Area: Urology.

phase 3 Antimuscarinic M3 receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

imidafenacin, KRP-197/ONO-8025 (imidafenacin, KRP-197/ONO-8025) — Ono Pharmaceutical Co. Ltd. Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
imidafenacin, KRP-197/ONO-8025 TARGET	imidafenacin, KRP-197/ONO-8025	Ono Pharmaceutical Co. Ltd	phase 3	Antimuscarinic	M3 receptor
Tudorza Pressair	ACLIDINIUM BROMIDE	Covis	marketed	Anticholinergic	M3 receptors, beta 2 -adrenergic receptors	2012-01-01
ACLIDINIUM	ACLIDINIUM		marketed		M3 receptors, beta 2 -adrenergic receptors	2012-01-01
TIOTROPIUM	TIOTROPIUM		marketed		M3 receptors, beta2-adrenoceptors	2004-01-01
Budesonide/Glycopyrronium/Formoterol Fumarate	Budesonide/Glycopyrronium/Formoterol Fumarate	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrronium)
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
umeclidinium 62.5 µg and vilanterol 25 µg	umeclidinium 62.5 µg and vilanterol 25 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimuscarinic class)

Ono Pharmaceutical Co. Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). imidafenacin, KRP-197/ONO-8025 — Competitive Intelligence Brief. https://druglandscape.com/ci/imidafenacin-krp-197-ono-8025. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab